Table 3 Clinical trials with CAR NK cells
From: CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
# | Clinical Trial identifier | Status | Clinical trial phase | Disease | Antigen | Interventions | Dosage | starting time |
|---|---|---|---|---|---|---|---|---|
1 | NCT03692663 | Not yet recruiting | Early Phase 1 | Castration-resistant Prostate Cancer | PSMA | anti-PSMA CAR NK cells | 0.5-3 × 10^6/kg | Dec-18 |
2 | NCT03690310 | Not yet recruiting | Early Phase 1 | Refractory B-Cell Lymphoma | CD19 | Anti-CD19 CAR NK Cells | 50-600 × 10^3/kg | Mar-19 |
3 | NCT03692767 | Not yet recruiting | Early Phase 1 | Refractory B-Cell Lymphoma | CD22 | Anti-CD22 CAR NK Cells | 50-600 × 10^3/kg | Mar-19 |
4 | NCT03692637 | Not yet recruiting | Early Phase 1 | Epithelial Ovarian Cancer | Mesothelin | anti-Mesothelin Car NK Cells | 0.5-3 × 10^6/kg | Mar-19 |
5 | NCT04639739 | Not yet recruiting | Early Phase 1 | NHL | CD19 | anti-CD19 CAR NK | 2 × 10^6/kg, 6 × 10^6/kg, 2 | Dec-20 |
6 | NCT04847466 | Not yet recruiting | Phase 2 | Gastroesophageal Junction (GEJ) Cancers|Advanced HNSCC | PD-L1 | PD-L1 t-haNK | 2 × 10^9 | Jul-21 |
7 | NCT03056339 | Recruiting | Phase 1/2 | B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic | CD19 | iC9/CAR.19/IL15-Transduced CB- | 1 × 10^5 | Jun-17 |
8 | NCT03383978 | Recruiting | Phase 1 | Glioblastoma | HER2 | NK-92/5.28.z | 1 × 10^7-1 × 10^8 | Dec-17 |
9 | NCT04887012 | Recruiting | Early Phase 1 | B-cell Non Hodgkin Lymphoma | CD19 | anti-CD19 CAR-NK | unknown | Mar-19 |
10 | NCT03940833 | Recruiting | Phase 1/2 | Multiple Myeloma | BCMA | BCMA CAR-NK 92 cells | unknown | May-19 |
11 | NCT03940820 | Recruiting | Phase 1/2 | Solid Tumor | ROBO1 | ROBO1 CAR-NK cells | unknown | May-19 |
12 | NCT03941457 | Recruiting | Phase 1/2 | Pancreatic Cancer | ROBO1 | BiCAR-NK cells (ROBO1 CAR-NK ce | unknown | May-19 |
13 | NCT03931720 | Recruiting | Phase 1/2 | Malignant Tumor | ROBO1 | BiCAR-NK/T cells (ROBO1 CAR-NK | unknown | May-19 |
14 | NCT04245722 | Recruiting | Phase 1 | Lymphoma, B-Cell|Chronic Lymphocytic Leukemia | CD19 | Drug: FT596|Drug: Cyclophospha | unknown | Mar-20 |
15 | NCT04555811 | Recruiting | Phase 1 | NHL|Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Hig | CD19 | Drug: FT596|Drug: Rituximab | (Dose Level 1: 9 × 10^7 c | Sep-20 |
16 | NCT04623944 | Recruiting | Phase 1 | Relapsed/Refractory AML|AML, Adult|MDS|Refractory Myelodys | NKG2DL | NKX101 - CAR NK cell therapy | Part 1/Regimen A: 1 × 10 | Sep-20 |
17 | NCT04747093 | Recruiting | Phase 1/2 | B Cell Leukemia|B Cell Lymphoma|B-cell Acute Lymphoblastic Leu | unknown | CaR-ITNK cells | unknown | Jan-21 |
18 | NCT04796675 | Recruiting | Phase 1 | Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|No | CD19 | CAR-NK-CD19 Cells | 0.01 × 10^7, 0.1 × 10^7, 1. | Apr-21 |
19 | NCT02742727 | Unknown status | Phase 1/2 | Acute Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemi | CD7 | anti-CD7 CAR-pNK cells | unknown | Mar-16 |
20 | NCT02839954 | Unknown status | Phase 1/2 | Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic | MUC1 | anti-MUC1 CAR-pNK cells | unknown | Jul-16 |
21 | NCT02892695 | Unknown status | Phase 1/2 | Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Fol | CD19 | anti-CD19 CAR-NK cells | unknown | Sep-16 |
22 | NCT02944162 | Unknown status | Phase 1/2 | Acute Myelogenous Leukemia|Acute Myeloid Leukemia|Acute | MCD33 | anti-CD33 CAR-NK cells | unknown | Oct-16 |
23 | NCT03415100 | Unknown status | Phase 1 | Solid Tumours | NKG2DL | CAR-NK cells targeting NKG2D liga | unknown | Jan-18 |
24 | NCT03824964 | Unknown status | Early Phase 1 | Refractory B-Cell Lymphoma | CD19/CD22 | Anti-CD19/CD22 CAR NK Cells | 50-600 × 10^3/kg | Feb-19 |